Exploring the influence of magnesium stearate content and mixing modality on the rheological properties and in vitro aerosolization of dry powder inhaler

Since carrier-based dry powder inhalers (DPIs) suffer from inadequate drug deposition in the lung, an increasing number of marketed products have added magnesium stearate (MgSt) to improve the aerosolization, dispersion, and stability against moisture of DPI. However, for carrier-based DPI, there is a lack of examination of the optimal MgSt content as well as the mixing modality, and there is also a need to verify the applicability of rheological properties to predict the in vitro aerosolization of DPI formulations containing MgSt. Therefore, in this work, DPI formulations were prepared using fluticasone propionate as a model drug and commercial crystalline lactose Respitose® SV003 as a carrier within 1% MgSt content, the effect of MgSt content on the rheological and aerodynamic properties were investigated.

After the optimal MgSt content was determined, the effects of mixing modality, mixing order, and carrier size on formulation properties were further investigated. Meanwhile, correlations were established between rheological parameters and in vitro drug deposition parameters, and the contribution of rheological parameters were determined using principal component analysis (PCA). The results showed that the optimal content of MgSt in DPI formulations is 0.25%-0.5% under both high-shear and low-shear, using medium-sized carriers (D50 around 70 μm) and low-shear mixing are beneficial for improving in vitro aerosolization.

Good linear relationships between powder rheological parameters such as basic flow energy (BFE), specific energy (SE), Permeability and fine particle fraction (FPF) were established, PCA showed that both flowability and adhesion are key properties affecting FPF. In conclusion, both MgSt content and mixing modality can influence rheological properties of the DPI, which can be used as a screeing tool for DPI formuluation and preparation process optimization.

Read more here

Materials

Fluticasone Propionate (FP) were provided by Bionna medicine (Bionna Medicine Co., Ltd., Beijing, China). Different particle sizes of inhalation grade lactose as the crude carrier, Respitose®SV003 (SV003), Lactohale®206 (LH206), and Lactohale®100 (LH100), respectively, were all provided by DFE Pharma (DFE Pharma, Shanghai, China). Magnesium stearate (LIGAMED® MF-2-V) was from Peter Greven provided by Fengli Jingqiu (Fengli Jingqiu Pharmaceutical Co., Ltd., Beijing, China).

Jiayi Li, Sibo Ma, Xianhong He, Ying Sun, Xin Zhang, Jian Guan, Shirui Mao, Exploring the influence of magnesium stearate content and mixing modality on the rheological properties and in vitro aerosolization of dry powder inhaler,
International Journal of Pharmaceutics, Volume 642, 2023, 123179, ISSN 0378-5173, https://doi.org/10.1016/j.ijpharm.2023.123179.

Read more and see the interesting video for Magnesium Stearate as a pharmaceutical excipient: